Kasper Bendix Johnsen

Kasper Bendix Johnsen

Auto-generated profile, based on publicly available information

Kasper Bendix Johnsen

Neurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, 9220 Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MTMaj Schneider Thomsen
Maj Schneider Thomsen
KJKasper Bendix Johnsen
Kasper Bendix Johnsen
KKKrzysztof Kucharz
Krzysztof Kucharz
MLMartin Lauritzen
Martin Lauritzen
TMTorben Moos
Torben Moos
The blood–brain barrier (BBB), built by brain endothelial cells (BECs), is impermeable to biologics. Liposomes and other nanoparticles are good candidates for the delivery of biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner. The liposomes need attachment of a targeting molecule, as BECs unfortunately are virtually incapable of uptake of non-targeted liposomes from the circulation. Experiments of independent research groups have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs. Functionalization of nanoparticles via conjugation with anti-transferrin receptor antibodies leads to nanoparticle uptake by endothelial cells of both brain capillaries and post-capillary venules. Reducing the density of transferrin receptor-targeted antibodies conjugated to liposomes limits uptake in BECs. Opposing the transport of nanoparticles conjugated to high-affine anti-transferrin receptor antibodies, lowering the affinity of the targeting antibodies or implementing monovalent antibodies increase uptake by BECs and allows for further transport across the BBB. The novel demonstration of transport of targeted liposomes in post-capillary venules from blood to the brain is interesting and clearly warrants further mechanistic pursuit. The recent evidence for passing targeted nanoparticles through the BBB shows great promise for future drug delivery of biologics to the brain.

1 January 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
KJKasper Bendix Johnsen
Kasper Bendix Johnsen
JGJohann Mar Gudbergsson
Johann Mar Gudbergsson
MDMeg Duroux
Meg Duroux
TMTorben Moos
Torben Moos
TAThomas Lars Andresen
Thomas Lars Andresen
JSJens Bæk Simonsen
Jens Bæk Simonsen

13 October 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MTMaj Schneider Thomsen
Maj Schneider Thomsen
KJKasper Bendix Johnsen
Kasper Bendix Johnsen
KKKrzysztof Kucharz
Krzysztof Kucharz
MLMartin Lauritzen
Martin Lauritzen
TMTorben Moos
Torben Moos
The blood-brain barrier (BBB), built by brain endothelial cells (BECs), is impermeable to biologics. Liposomes and other nanoparticles are good candidates for delivery of biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner. The liposomes need attachment of a targeting molecule, as BECs unfortunately are virtually incapable of uptake of non-targeted liposomes from the circulation. Experiments of independent research groups have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs. Functionalization of nanoparticles via conjugation with anti-transferrin receptor antibodies leads to nanoparticle uptake by endothelial cells of both brain capillaries and post-capillary venules. Reducing the density of transferrin receptor-targeted antibodies conjugated to liposomes limits uptake in BECs. Opposing the transport of nanoparticles conjugated to high-affine anti-transferrin receptor antibodies, lowering the affinity of the targeting antibodies or implementing monovalent antibodies increase uptake by BECs and allows for further transport across the BBB. The novel demonstration of transport of targeted liposomes in post-capillary venules from blood to the brain is interesting and clearly warrants further mechanistic pursuit. The recent evidence for passing targeted nanoparticles through the BBB shows great promise for future drug delivery of biologics to the brain.